EUCTR2009-012714-49-FR进行中（未招募）不适用
Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy - LAPAINBLAD
CHU de Bordeaux0 个研究点目标入组 15 人开始时间: 2009年9月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- •-> Patients must sign and date IRB/EC-approved informed consent.
- •-> Age = 18.
- •-> A female is eligible to enter and participate in this study if she is of:
- •- Non-child-bearing potential (i.e., a woman with functioning ovaries who have a current documented tubal ligation or hysterectomy or a woman who is menopausal), or
- •- child-bearing potential (i.e. a woman with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility. This category includes women with oligomenorrhoea (even severe), women who are perimenopausal and young women who have begun to menstruate), who have a negative serum pregnancy test at screening, and agree to one of the following,
- •- Consistent and correct use of one of the following acceptable methods of birth control, or
- •- Any intrauterine device (IUD) with a documented failure rate of less than 1% per yearn or
- •- Combined oral contraception,
- •-> Care must be taken to avoid pregnancy in partners of male patients,
- •-> Patients must have a life expectancy of at least 6 months,
- •-> Patients must have a Karnofsky performance status = 80%,
- •-> Clinical stage T2NxM0 to T4aNxM0 bladder cancer,
- •-> Muscle-invasive transitional cell carcinoma by histology (focal squamous and/or adenocarcinoma differentiation defined as = 10% of tumor volume allowed, sarcomatoid and small-cell components not allowed),
- •-> Considered to have a macroscopic residue in the bladder to allow comparison of tissue samples at cystectomy to initial biopsies,
- •-> Candidates for radical cystectomy,
- •-> Patient with normal cardiac function, LVEF = 50% measured by echocardiography or MUGA scan,
- •-> Able to swallow and retain oral medication,
- •-> Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures,
- •-> Affiliated or profit patient of a social security system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-> Prior pelvic radiation or neoadjuvant chemotherapy.
- •-> Pregnancy or breastfeeding.
- •-> Other severe acute or chronic medical or psychiatric condition that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •-> Patients with significantly reduced LVEF or LVEF < 50%.
- •-> Patient with any of the following liver abnormal laboratory test :
- •- Serum bilirubin > 1,5 x upper limit of normal (ULN) (in case of Gilbert syndrome, a higher serum total bilirubin (< 2 ULN) is allowed
- •- Alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) > 2,5 ULN
- •- Platelets ? 100 x 109/L, hemoglobin > 9 g/dl, absolute neutrophil count (ANC) >1.5 x 109/L
- •-> Serum creatinine < 1.5 x ULN.
- •-> Previous therapy targeting EGFR or HER-2.
- •-> Predominantly non transitional cell histology.
- •-> Pregnant or lactating females. NOTE: A negative pregnancy test must be documented during the screening period for women of childbearing potential
- •-> Diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months.
- •-> Malabsorption syndrome, disease significantly affecting gastrointestinal function, or major resection of the stomach or bowel, that could affect absorption of lapatinib.
- •-> History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
- •-> Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements.
- •- History of uncontrolled or symptomatic angina
- •- History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation
- •- Myocardial infarction < 6 months from study entry
- •- Uncontrolled or symptomatic congestive heart failure
- •- Ejection fraction below the institutional normal limit
- •- Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- •-> Use of an investigational agent within 30 days or 5 half-lives, whichever is the longer, preceding the first dose of investigational product.
- •-> Concurrent treatment with an investigational agent
- •-> Concurrent treatment with cytotoxic chemotherapy, immunotherapy, biologic therapy, hormonal therapy or curative radiotherapy for locally advanced or metastatic TCC of the urothelial tract.
- •-> Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.
- •-> Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •-> Patient under safeguard of justice
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
招募中
2 期
LENVABLA Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by percutaneous ablation procedure in a curative intent: multicentre pilot therapeutic trial2024-514606-31-00Assistance Publique Hopitaux De Paris50
已完成
2 期
Phase II study of lapatinib plus capecitabin for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents.Breast cancerJPRN-UMIN000002456Saitama Breast Cancer Clinical Study Group(SBCCSG)30
已完成
不适用
Phase I/II study with lapatinib plus trametinib in patients with metastatic KRAS mutant non-small cell lung cancer10038666non-small cell lung cancerNL-OMON46994Antoni van Leeuwenhoek Ziekenhuis132
进行中（未招募）
1 期
Phase I/II study with lapatinib plus trametinib in patients with metastaticnon-small cell lung cancer with a mutation in the KRAS genenon-small cell lung cancerEUCTR2014-002209-39-NLThe Netherlands Cancer Institute132